Clinical Outcomes by Age in Men With Hormone Refractory Prostate Cancer: A Pooled Analysis of 8 Cancer and Leukemia Group B (CALGB) Studies

Journal of Urology

Volumn 176, Issue 1, 2006, Pages 81-86

  Halabi, Susan ^a,b   Vogelzang, Nicholas J ^c   Ou, San San ^b   Kelly, Wm Kevin ^d   Small, Eric J ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

mortality; outcome assessment (health care); prostate; prostatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GROUPS BY AGE; HEMATOLOGY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RISK FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 33744534509     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(06)00566-0     Document Type: Article

References (20)

1. Jemal A., Murray T., Ward E., Samuel A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. Cancer J Clin 55 (2005) 10 CA
2. Ries L.A.G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L.X., et al. SEER Cancer Statistics Review 1973-1998 (2000), National Cancer Institute, National Institutes of Health Publication No. 00-2789, Bethesda, Maryland
3. Tarone R.E., Chu K.C., and Brawley O.W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11 (2000) 167
4. Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A., et al. A prognostic model for predicting overall survival in men with advanced prostate cancer. J Clin Oncol 21 (2003) 1232
5. Picus J., Halabi S., Rini B., Vogelzang N., Whang Y., Kaplan E., et al. The use of bevacizumab (B) and docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC). initial results of CALGB 90006. Proc Am Soc Clin Oncol 22 (2003) 393
6. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457
7. Cox D.R. Regression models and life tables. J R Stat Soc B 74 (1972) 187
8. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 69 (1982) 239
9. Byar D.P., and Mostofi F.K. Cancer of the prostate in men less than 50 years old. an analysis of 51 cases. J Urol 102 (1969) 726
10. Johnson D.E., Lanieri J.P., and Ayala A.G. Prostatic adenocarcinoma occurring in men under 50 years of age. J Surg Oncol 4 (1972) 207
11. Routh A., Hickman B.T., Meydrech E., Bass J.D., and Moulder J.T. Survival of carcinoma of the prostate patients less than 55 years old compared to older patient groups. J Miss State Med Assoc 38 (1997) 1
12. Pienta K.J., Demers R., Hoff M., Kau T.Y., Montie J.E., and Severson R.K. Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tricounty area, 1973 to 1987. Urology 45 (1995) 93
13. Lu-Yao G.L., Albertsen P., Warren J., and Yao S.L. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy-a population-based study. Urology 54 (1999) 301
14. Obek C., Lai S., Sadek S., Civantos F., and Soloway M.S. Age as a prognostic factor for disease recurrence after radical prostatectomy. Urology 54 (1998) 533
15. Carter H.B., Epstein J.I., and Partin A.W. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 53 (1999) 126
16. Herold D.M., Hanlon A.L., Movsas B., and Hanks G.E. Age-related prostate cancer metastases. Urology 51 (1998) 985
17. Harlan L., Brawley O., Pommerenke F., Wali P., and Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 13 (1995) 93
18. Meltzer D., Egleston B., and Abdalla I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 91 (2001) 126
19. Thompson I.M., Tangen C.M., Tolcher A., Crawford E., Eisenberger M., and Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 93 (2001) 219
20. Halabi S., Small E.J., Vogelzang N.J., Barrier Jr. R.C., George S.L., and Gilligan T.D. Impact of race on survival in men with metastatic hormone refractory prostate cancer. Urology 64 (2004) 212